Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

MediXall (MDXL) Net Margin (2021 - 2024)

MediXall's Net Margin history spans 4 years, with the latest figure at 595.04% for Q3 2024.

  • For Q3 2024, Net Margin rose 210120.0% year-over-year to 595.04%; the TTM value through Sep 2024 reached 798.78%, up 141444.0%, while the annual FY2023 figure was 1576.1%, 1047731.0% up from the prior year.
  • Net Margin reached 595.04% in Q3 2024 per MDXL's latest filing, up from 1067.39% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 595.04% in Q3 2024 to a low of 40730.69% in Q1 2021.
  • Average Net Margin over 4 years is 11725.6%, with a median of 1667.96% recorded in 2023.
  • The largest YoY upside for Net Margin was 3301148bps in 2022 against a maximum downside of -1469149bps in 2022.
  • A 4-year view of Net Margin shows it stood at 26364.48% in 2021, then soared by 65bps to 9195.46% in 2022, then surged by 82bps to 1622.76% in 2023, then surged by 137bps to 595.04% in 2024.
  • Per Business Quant, the three most recent readings for MDXL's Net Margin are 595.04% (Q3 2024), 1067.39% (Q2 2024), and 478.01% (Q1 2024).